As an investigator with the prestigious Thrombolysis in Myocardial Infarction (TIMI) Study Group he has played important roles in the planning, implementation and interpretation of several multicenter, national and international clinical trials.  He has played leadership roles in the JUMBO – TIMI 26 trial and the TRITON – TIMI 38 trial the major phase 2 and phase 3 trials of prasugrel a third generation thienopyridine.  He was the Principal Investigator of PRINCIPLE – TIMI 44, a study comparing high-dose clopidogrel with prasugrel in patients undergoing PCI and of the TIMI 38 Coronary Stent Registry, an ongoing international registry of the long-term outcomes of patients receiving different types of intracoronary stents for acute coronary syndromes.  He serves as the physician chairman of the TIMI Clinical Events Committee.

Dr. Wiviott is an author of more than fifty peer-reviewed publications in major medical and cardiovascular journals.  He is the author of multiple chapters in major cardiovascular textbooks including Cardiovascular Therapeutics, a companion to Braunwald’s Heart Disease.  He has delivered local, national and international lectures in the field of acute coronary syndromes, platelet biology, established and novel antiplatelet agents.  Areas of clinical and research interest include acute coronary syndromes, platelet biology, platelet inhibitors, and cholesterol lowering therapy.   

Dr. Wiviott is a general Cardiologist on staff at Brigham and Women’s Hospital attending on the Coronary Care Unit, and the inpatient Cardiology and Cardiology Consultation services.  He is active in clinical teaching of Cardiology Fellows, Internal Medicine Housestaff, and Harvard Medical Students.  He serves as a faculty member of Harvard Medical School teaching Cardiovascular Pathophysiology.